# Avax One Technology LTD.: financial statements, quarterly

AVX · Nasdaq · CIK 1826397 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avx.md) · [Financials](/companies/avx/financials.md) · [Filings](/companies/avx/filings.md) · [Insiders](/companies/avx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001641172-25-024019.md) | [0.0 d](/filings/0001493152-24-046821.md) | [(0.0) d](/filings/0001493152-26-014138.md) | [0.3](/filings/0001493152-26-023348.md) | [0.5](/filings/0001493152-26-037763.md) | [0.5](/filings/0001493152-25-023464.md) | [1.1 d](/filings/0001493152-26-014138.md) | [2.5](/filings/0001493152-26-023348.md) | [2.8](/filings/0001493152-26-037763.md) |
| Cost of revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001493152-24-031696.md) | [0.0 d](/filings/0001493152-24-046821.md) | [0.1 d](/filings/0001641172-25-002955.md) | [0.3](/filings/0001641172-25-010961.md) | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | [0.0](/filings/0001493152-24-031696.md) | [(0.0) d](/filings/0001493152-24-046821.md) | [(0.0) d](/filings/0001641172-25-002955.md) | [0.1](/filings/0001641172-25-010961.md) | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [(0.0)](/filings/0001493152-24-046821.md) | [(0.0) d](/filings/0001641172-25-002955.md) | [0.0](/filings/0001641172-25-010961.md) | [0.0](/filings/0001641172-25-024019.md) | [0.1](/filings/0001493152-24-046821.md) | [0.0 d](/filings/0001493152-26-014138.md) | [0.2](/filings/0001641172-25-010961.md) | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | [1.3](/filings/0001493152-26-023348.md) | [1.2](/filings/0001493152-26-037763.md) | not reported | not reported | [2.3](/filings/0001493152-26-023348.md) | [2.2](/filings/0001493152-26-037763.md) |
| Operating income | $m | [(1.6)](/filings/0001493152-24-046821.md) | [(3.8) d](/filings/0001641172-25-002955.md) | [(1.3)](/filings/0001641172-25-010961.md) | [(1.2)](/filings/0001641172-25-024019.md) | [(5.5)](/filings/0001493152-25-023464.md) | [(2.1) d](/filings/0001493152-26-014138.md) | [(1.8)](/filings/0001493152-26-023348.md) | [(1.4)](/filings/0001493152-26-037763.md) | [(2.6)](/filings/0001493152-25-023464.md) | [(15.7) d](/filings/0001493152-26-014138.md) | [(44.6)](/filings/0001493152-26-023348.md) | [(33.4)](/filings/0001493152-26-037763.md) |
| Net income | $m | [(3.5)](/filings/0001493152-24-046821.md) | [(4.0) d](/filings/0001641172-25-002955.md) | [(3.3)](/filings/0001641172-25-010961.md) | [(4.2)](/filings/0001641172-25-024019.md) | [(5.8)](/filings/0001493152-25-023464.md) | [(2.9) d](/filings/0001493152-26-014138.md) | [(0.1)](/filings/0001493152-26-023348.md) | [(8.1)](/filings/0001493152-26-037763.md) | [(8.4)](/filings/0001493152-25-023464.md) | [(16.6) d](/filings/0001493152-26-014138.md) | [(46.4)](/filings/0001493152-26-023348.md) | [(35.1)](/filings/0001493152-26-037763.md) |
| Diluted EPS | $ per share | [(4.03)](/filings/0001493152-24-046821.md) | not reported | [(26.32)](/filings/0001641172-25-010961.md) | [(83.03)](/filings/0001641172-25-024019.md) | [(57.19)](/filings/0001493152-25-023464.md) | not reported | [(10.57)](/filings/0001493152-26-023348.md) | [(335.88)](/filings/0001493152-26-037763.md) | [(5.55)](/filings/0001493152-25-023464.md) | not reported | [(0.48)](/filings/0001493152-26-023348.md) | [(4.41)](/filings/0001493152-26-037763.md) |
| Basic EPS | $ per share | [(4.03)](/filings/0001493152-24-046821.md) | not reported | [(26.32)](/filings/0001641172-25-010961.md) | [(83.03)](/filings/0001641172-25-024019.md) | [(57.19)](/filings/0001493152-25-023464.md) | not reported | [(0.78)](/filings/0001493152-26-023348.md) | [(335.88)](/filings/0001493152-26-037763.md) | [(5.55)](/filings/0001493152-25-023464.md) | not reported | [(0.48)](/filings/0001493152-26-023348.md) | [(4.41)](/filings/0001493152-26-037763.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.6](/filings/0001493152-23-039152.md) | [3.9](/filings/0001641172-25-002955.md) | [2.9](/filings/0001493152-24-019561.md) | [2.9](/filings/0001493152-24-031696.md) | [1.4](/filings/0001493152-24-046821.md) | [0.5](/filings/0001493152-26-014138.md) | [1.4](/filings/0001641172-25-010961.md) | [0.2](/filings/0001641172-25-024019.md) | [0.9](/filings/0001493152-25-023464.md) | [22.1](/filings/0001493152-26-037763.md) | [16.5](/filings/0001493152-26-023348.md) | [11.4](/filings/0001493152-26-037763.md) |
| Current assets | $m | [1.2](/filings/0001493152-23-039152.md) | [4.2](/filings/0001641172-25-002955.md) | [3.3](/filings/0001493152-24-019561.md) | [3.3](/filings/0001493152-24-031696.md) | [1.9](/filings/0001493152-24-046821.md) | [1.3](/filings/0001493152-26-014138.md) | [2.9](/filings/0001641172-25-010961.md) | [1.4](/filings/0001641172-25-024019.md) | [3.0](/filings/0001493152-25-023464.md) | [33.5](/filings/0001493152-26-037763.md) | [38.9](/filings/0001493152-26-023348.md) | [32.2](/filings/0001493152-26-037763.md) |
| Total assets | $m | [17.3](/filings/0001493152-23-039152.md) | [17.4](/filings/0001641172-25-002955.md) | [16.0](/filings/0001493152-24-019561.md) | [15.7](/filings/0001493152-24-031696.md) | [10.8](/filings/0001493152-24-046821.md) | [10.8](/filings/0001493152-26-014138.md) | [16.8](/filings/0001641172-25-010961.md) | [15.2](/filings/0001641172-25-024019.md) | [16.5](/filings/0001493152-25-023464.md) | [195](/filings/0001493152-26-037763.md) | [157](/filings/0001493152-26-023348.md) | [123](/filings/0001493152-26-037763.md) |
| Current liabilities | $m | [6.9](/filings/0001493152-23-039152.md) | [6.0](/filings/0001641172-25-002955.md) | [4.0](/filings/0001493152-24-019561.md) | [2.6](/filings/0001493152-24-031696.md) | [3.2](/filings/0001493152-24-046821.md) | [4.3](/filings/0001493152-26-014138.md) | [8.5](/filings/0001641172-25-010961.md) | [11.1](/filings/0001641172-25-024019.md) | [4.3](/filings/0001493152-25-023464.md) | [8.0](/filings/0001493152-26-014138.md) | not reported | not reported |
| Total liabilities | $m | [10.0](/filings/0001493152-23-039152.md) | [8.8](/filings/0001641172-25-002955.md) | [7.0](/filings/0001493152-24-019561.md) | [4.3](/filings/0001493152-24-031696.md) | [4.1](/filings/0001493152-24-046821.md) | [4.7](/filings/0001493152-26-014138.md) | [10.4](/filings/0001641172-25-010961.md) | [11.2](/filings/0001641172-25-024019.md) | [4.4](/filings/0001493152-25-023464.md) | [8.0](/filings/0001493152-26-037763.md) | [14.3](/filings/0001493152-26-023348.md) | [14.9](/filings/0001493152-26-037763.md) |
| Long-term debt | $m | [10.7](/filings/0001493152-23-039152.md) | [11.5](/filings/0001493152-24-012418.md) | [7.9](/filings/0001493152-24-019561.md) | [3.1](/filings/0001493152-24-031696.md) | [2.2](/filings/0001493152-24-046821.md) | [1.5](/filings/0001641172-25-002955.md) | [10.2](/filings/0001641172-25-010961.md) | [8.6](/filings/0001641172-25-024019.md) | [1.8](/filings/0001493152-25-023464.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [7.4](/filings/0001493152-24-046821.md) | [8.6](/filings/0001493152-26-014138.md) | [8.9](/filings/0001641172-25-024019.md) | [11.3](/filings/0001493152-25-023464.md) | [6.7](/filings/0001493152-25-023464.md) | [6.1](/filings/0001493152-26-037763.md) | [6.4](/filings/0001493152-26-037763.md) | [4.1](/filings/0001493152-26-037763.md) | [12.2](/filings/0001493152-25-023464.md) | [187](/filings/0001493152-26-037763.md) | [143](/filings/0001493152-26-037763.md) | [108](/filings/0001493152-26-037763.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,098) d](/filings/0001493152-24-046821.md) | [(1,067) d](/filings/0001641172-25-002955.md) | [(1,309)](/filings/0001641172-25-010961.md) | [(919) d](/filings/0001641172-25-024019.md) | [(1,201) d](/filings/0001493152-25-023464.md) | [(1,842) d](/filings/0001493152-26-014138.md) | [(2,173)](/filings/0001493152-26-023348.md) | [(884) d](/filings/0001493152-26-037763.md) | [(2,377) d](/filings/0001493152-25-023464.md) | [(9,012) d](/filings/0001493152-26-014138.md) | [(1,349)](/filings/0001493152-26-023348.md) | [(3,722) d](/filings/0001493152-26-037763.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [2,523](/filings/0001493152-26-023348.md) | [0.0 d](/filings/0001493152-26-037763.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [3,044](/filings/0001493152-26-023348.md) | [806 d](/filings/0001493152-26-037763.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [409](/filings/0001493152-23-039152.md) | [475](/filings/0001493152-24-019561.md) | [499](/filings/0001493152-24-031696.md) | [867](/filings/0001493152-24-046821.md) | [126](/filings/0001641172-25-010961.md) | [51.0](/filings/0001641172-25-024019.md) | [102](/filings/0001493152-25-023464.md) | [0.6](/filings/0001493152-26-023348.md) | [0.0](/filings/0001493152-26-037763.md) | [1,505](/filings/0001493152-25-023464.md) | [97.5](/filings/0001493152-26-023348.md) | [8.0](/filings/0001493152-26-037763.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 7,397,383 at 2026-08-12, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037763.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.